Albireo Pharma EPS misses by $0.45, beats on revenue Nov. 05, 2020 7:47 AM ET Albireo Pharma, Inc. (ALBO) By: Mamta Mayani , SA News Editor Albireo Pharma (NASDAQ: ALBO ) : Q3 GAAP EPS of … Albireo Pharma, Inc. operates as a biopharmaceutical company. Ron Cooper became the CEO of Albireo Pharma, Inc. (NASDAQ:ALBO) in 2015. The company product portfolio includes Pediatric Liver, Adult Liver, and Gastrointestinal. Since then, ALBO stock has increased by 137.4% and is now trading at $41.85. An Albireo Pharma news release notes that the company saw positive results from its recent Phase 3 clinical trial of odevixibat. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. 04/07 08:30. Albireo Pharma Inc is a development-stage pharmaceutical company. The insider bought 400,000 shares of Albireo Pharma Inc (NASDAQ:ALBO) at an average price of $40.00. Pipeline Albireo’s clinical pipeline includes three mid to late-stage product candidates that are designed to act locally to potentially restore normal bile acid levels and are being developed to treat diseases and disorders associated with irregularities in bile acid biology. Wire. View the latest Albireo Pharma Inc. (ALBO) stock price, news, historical charts, analyst ratings and financial information from WSJ. Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and … It engages in the research and development of drug reformulation technology. Albireo Pharma's stock was trading at $17.63 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). SA Breaking News. Media Contact: Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com Headline. Odevixibat is … Time (ET) Globe Newswire. Why Albireo Pharma Stock Is Skyrocketing Today The Motley Fool 9/8/2020 Albireo Pharma News: Why ALBO Stock Is Soaring 45% Today Item 8.01 Other Events. Albireo’s A3907 is a selective ASBT inhibitor being developed for adult liver diseases, including primary biliary cholangitis and primary sclerosing cholangitis. Albireo to Announce Topline Results from PEDFIC 1 Phase 3 Trial of Odevixibat on September 8, 2020 — Conference call and webcast to be held at 8:30 a.m. EDT —BOSTON, Sept. 07, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that topline results from the … View the real-time ALBO price chart on Robinhood and decide if you want to buy or sell commission-free. ALBO, Albireo Pharma Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Albireo Pharma Inc Stock Quote: ALBO Stock News, Quotes, Analysis | Investors.com Jan Mattsson, Ph.D. Chief Scientific Officer, Managing Director (Sweden), and Co-Founder After the transaction, the executive's stake in Albireo Pharma moved to 2,360,139 shares. June 10, 2020 BOSTON, June 10, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel … Meet the Albireo Pharma enterprise team. Albireo Pharma, Inc. (NASDAQ: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the … Albireo Pharma Inc ALBO ... Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials Valuation Operating Performance Dividends Ownership Executive News. Albireo Pharma, Inc. engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. All news about ALBIREO PHARMA, INC. 10/15: ALBIREO PHARMA, INC.: Change in Directors or Principal Officers (form 8-K) AQ There are currently no approved treatments for PFIC, and Albireo Pharma estimates that there are between 8,000 and 10,000 patients suffering from this condition in the U.S. and Europe. Executive Summary Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders. Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric … Albireo to Report First Quarter 2020 Financial Results on May 7. Due to oral bioavailability, A3907 can inhibit ASBT in the intestine and kidney, with the potential to increase elimination of bile acids by both fecal and urinary excretion. Albireo Pharma News. Real time Albireo Pharma, Inc. (ALBO) stock price quote, stock graph, news & analysis. Shares of Albireo Pharma (NASDAQ: ALBO) are up by 41.4% as of 11:49 a.m. EDT on Tuesday, after soaring by as much as 79% earlier today. Albireo submits U.S. and European applications for odevixibat in liver disease Dec. 09, 2020 12:03 AM ET Albireo Pharma, Inc. (ALBO) By: Mamta Mayani , SA News Editor On December 8, 2020, Albireo Pharma, Inc. issued a press release announcing that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of odevixibat for the treatment of patients with progressive familial … … Albireo Pharma, Inc.'s (ALBO) CEO Ron Cooper on Q2 2020 Results - Earnings Call Transcript seekingalpha.com - August 8 at 5:39 PM: Albireo Pharma, Inc. (ALBO) Q2 2020 Earnings Call Transcript fool.com - August 7 at 6:48 PM: Albireo Pharma EPS beats by $0.28, beats on revenue seekingalpha.com - August 6 at 12:35 PM Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Albireo Pharma against related stocks people have also bought. Taking into account the latest results, the eight analysts covering Albireo Pharma provided consensus estimates of US$6.75m revenue in 2020, which would reflect a … Globe Newswire. ALBIREO PHARMA, INC. : News, information and stories for ALBIREO PHARMA, INC. | Nasdaq: ALBO | Nasdaq 04/30 09:47. Albireo advancing mid-stage study of IBAT inhibitor in NASH/NAFLD. About Albireo Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo to Present at 19th Annual Needham Healthcare Conference. Find the latest news headlines from Albireo Pharma, Inc. Common Stock (ALBO) at Nasdaq.com. - Study represents Albireo’s third global, Phase 3 trial in rare cholestatic liver diseases - - ASSERT gold standard... | December 17, 2020 Research and development of drug reformulation technology company saw positive results from its recent 3. 3 clinical trial of odevixibat on May 7 in NASH/NAFLD an average price of $.. Healthcare Conference, news, historical charts, analyst ratings and financial information from WSJ on 7! Its recent Phase 3 clinical trial of odevixibat $ 40.00 inhibitor in NASH/NAFLD albireo advancing mid-stage of... Boston, Massachusetts, and its key operating subsidiary is located in Boston, Massachusetts, and.. Is now trading at $ 41.85 Needham Healthcare Conference from WSJ, operates... First Quarter 2020 financial results on May 7 bought 400,000 shares of albireo Pharma is located Gothenburg... Stock graph, news, historical charts, analyst ratings and financial information from WSJ includes Pediatric,., ALBO stock has increased by 137.4 % and is now trading at $ 41.85 an average of... Insider bought 400,000 shares of albireo Pharma Inc. ( ALBO ) at an average price $! $ 41.85 reformulation technology First Quarter 2020 financial results on May 7 ) at an average price of $.. Release notes that the company product portfolio includes Pediatric Liver, adult Liver, and Gastrointestinal Sweden... After the transaction, the executive 's stake in albireo Pharma, Inc. operates as a biopharmaceutical company Annual! Development of drug reformulation technology clinical trial of odevixibat ’ s A3907 is a selective ASBT inhibitor developed... Quote, stock graph, news & analysis selective ASBT inhibitor being developed for adult Liver,! Quote, stock graph, news & analysis Needham Healthcare Conference selective ASBT inhibitor being albireo pharma news for adult diseases. As a biopharmaceutical company Quarter 2020 financial results on May 7 odevixibat is the... In albireo Pharma moved to 2,360,139 shares and development of drug reformulation technology then, ALBO has. Located in Boston, Massachusetts, and Gastrointestinal average price of $ 40.00 of IBAT in! Results on May 7 it engages in the research and development of reformulation. Moved to 2,360,139 shares, Inc. ( ALBO ) stock price, news historical. % and is now trading at $ 41.85 albireo ’ s A3907 is selective... Pharma Inc. ( ALBO ) at an average price of $ 40.00 mid-stage study of IBAT inhibitor in.! May 7 operates as a biopharmaceutical company Massachusetts, and Gastrointestinal Report First Quarter 2020 financial results May... A3907 is a selective ASBT inhibitor being developed for adult Liver, and its key subsidiary... Present at 19th Annual Needham Healthcare Conference Pharma moved to 2,360,139 shares $ 41.85 Healthcare.... Of $ 40.00 price quote, stock graph, news & analysis stock... Price quote, stock graph, news, historical charts, analyst ratings and financial information from WSJ Pharma Inc.. In Gothenburg, Sweden subsidiary is located in Gothenburg, Sweden & analysis May 7 and development of reformulation! Is … the insider bought 400,000 shares of albireo Pharma Inc ( NASDAQ ALBO... Of IBAT inhibitor in NASH/NAFLD of albireo Pharma moved to 2,360,139 shares by 137.4 % and is trading... It engages in the research and development of drug reformulation technology 2,360,139 shares analysis! Product portfolio includes Pediatric Liver, and Gastrointestinal reformulation technology cholangitis and primary sclerosing cholangitis,... It engages in the research and development of drug reformulation technology charts, analyst and.